Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Resverlogix Corp T.RVX

Alternate Symbol(s):  RVXCF

Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the treatment of cardiovascular disease and associated comorbidities, and post-COVID-19 conditions. RVX-208 is a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. RVX-208 is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. It partners with EVERSANA, to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.


TSX:RVX - Post by User

Bullboard Posts
Comment by SanFrancisco99on May 08, 2014 9:52am
254 Views
Post# 22537950

RE:RE:RE:RE:RE:RVX - EVENTS/WEBCASTS section updated...

RE:RE:RE:RE:RE:RVX - EVENTS/WEBCASTS section updated...I totally disagree JK, respectfully so.

Here's my two cents:  I think the spinout of Zenith last year was a brilliant idea.  It took the core assets and protected them from market gyrations.  We have witnessed those market gyration with RVX, so it was obviously a fantastic defensive move.  It also tells a buyer that if they want the crown jewels, they have to deal with the control group who are firmly in charge of that private company.  Thankfully so in my view.

I suspect (personal opinion here) that the fancy new laboratory and offices are an expansion - with further expansion perhaps being anticipated.  Zenith will either continue as an independent company - one that is expanding and needs a new office/laboratory to go OR is being sold off and the new office will become the low-cost, epigenetic research center in Calgary for the pharma buyer.

As for Resverlogix, I think that asset will be sold off and so the use of the office (perhaps a sublease from Zenith) could be short-term.

All of this is personal opinion.  But it is my personal opinion.  And it shows that the doomsday scenarios on this board about a move to a shiny new office might just be silly speculations.

Someone ought to get into their car and go see the new digs and report back here.




Bullboard Posts